ERG240
ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease[1].
Product Specifications
CAS Number
1415683-79-2
UNSPSC
12352211
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/egr240.html
Purity
98.0
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(CCC(C)C(C)=O)O[Na]
Molecular Formula
C7H11NaO3
Molecular Weight
166.15
References & Citations
[1]Papathanassiu, et al. Methods for treatment of cancer, inflammatory autoimmune disorders and bone diseases using branched-chain amino acid aminotransferase-1 (BCAT1) inhibitors. Patent. WO2012173987.|[2]Papathanassiu AE, et al. BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Nat Commun. 2017 Jul 12;8:16040.|[3]Papathanassiu A E, et al. Inhibition of BCAT1 suppresses the expression of pro-metastatic proteins and reduces cancer metastasis[J]. Cancer Research, 2014, 74 (19_Supplement) : 2683-2683.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880492-100 1x 100 µL
Moesin (MSN/492), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
